In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures

Executive Summary

AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.

You may also be interested in...



Facing Manufacturing Woes, Alexion Strengthens Leadership

Martin Mackay, who left AstraZeneca at the end of January after new CEO Pasqual Soriot eliminated his position as head of global R&D, is joining Alexion’s senior management team, even as the highly successful, rare disease-focused biotech seeks to put manufacturing woes behind it.

New Ecosystems In Pharma: Maturing Markets Mean New Models Are Needed

Success in the pharmaceutical industry requires new thinking about segmentation of drug markets and new insight into how the opportunity for pharma companies is changing. Oliver Wyman’s ecosystems framework attempts to determine where unmet medical need, innovation, and a strong value proposition for payors reside.

AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia (Part 2 of 2)

Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel